Paratek Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PRTK)

$13.35 +0.15 (+1.14 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$13.35
Today's Range$12.95 - $13.45
52-Week Range$11.85 - $29.00
Volume294,682 shs
Average Volume582,624 shs
Market Capitalization$377.25 million
P/E Ratio-3.58
Dividend YieldN/A
Beta0.27

About Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:PRTK
CUSIP89354M10
Phone+1-617-8076600

Debt

Debt-to-Equity Ratio0.49%
Current Ratio10.53%
Quick Ratio10.53%

Price-To-Earnings

Trailing P/E Ratio-3.57908847184987
Forward P/E Ratio-4.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$30,000.00
Price / Sales13,839.50
Cash FlowN/A
Price / CashN/A
Book Value$3.16 per share
Price / Book4.22

Profitability

Trailing EPS($3.73)
Net Income$-111,630,000.00
Net Margins-1,236.38%
Return on Equity-100.84%
Return on Assets-58.71%

Miscellaneous

Employees50
Outstanding Shares31,100,000

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) announced its quarterly earnings results on Monday, May, 2nd. The specialty pharmaceutical company reported ($1.77) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.25) by $0.52. Paratek Pharmaceuticals had a negative net margin of 1,236.38% and a negative return on equity of 100.84%. View Paratek Pharmaceuticals' Earnings History.

When will Paratek Pharmaceuticals make its next earnings announcement?

Paratek Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for Paratek Pharmaceuticals.

Where is Paratek Pharmaceuticals' stock going? Where will Paratek Pharmaceuticals' stock price be in 2018?

7 analysts have issued 1 year target prices for Paratek Pharmaceuticals' stock. Their forecasts range from $30.00 to $56.00. On average, they expect Paratek Pharmaceuticals' share price to reach $42.71 in the next twelve months. View Analyst Ratings for Paratek Pharmaceuticals.

Who are some of Paratek Pharmaceuticals' key competitors?

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the folowing people:

  • Michael F. Bigham CPA, Chairman of the Board, Chief Executive Officer (Age 59)
  • Evan Loh M.D., President, Chief Operating Officer, Chief Medical Officer, Director (Age 58)
  • Douglas W. Pagan, Chief Financial Officer (Age 45)
  • William M. Haskel, Senior Vice President, General Counsel, Corporate Secretary (Age 56)
  • Jeanne Jew, Senior Vice President - Business Development
  • Evan Tzanis, Senior Vice President - Clinical Development and Clinical Operations
  • Adam Woodrow, Vice President and Chief Commercial Officer (Age 50)
  • Thomas John Dietz, Independent Director (Age 53)
  • Timothy R. Franson M.D., Independent Director (Age 65)
  • Richard J. Lim, Independent Director (Age 45)

Who owns Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.12%), C WorldWide Group Holding A S (1.98%), Renaissance Technologies LLC (1.45%), Deutsche Bank AG (1.21%), Royce & Associates LP (1.16%) and General American Investors Co. Inc. (0.99%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega, Michael Bigham and Robert S Radie. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Who sold Paratek Pharmaceuticals stock? Who is selling Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Millennium Management LLC, General American Investors Co. Inc., Falcon Point Capital LLC, Essex Investment Management Co. LLC, C WorldWide Group Holding A S and BlackRock Inc.. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham and Robert S Radie. View Insider Buying and Selling for Paratek Pharmaceuticals.

Who bought Paratek Pharmaceuticals stock? Who is buying Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Prosight Management LP, Water Island Capital LLC, Renaissance Technologies LLC, Stansberry Asset Management LLC, Royce & Associates LP, Lazard Asset Management LLC and TIAA CREF Investment Management LLC. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy Paratek Pharmaceuticals stock?

Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $13.35.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $377.25 million and generates $30,000.00 in revenue each year. The specialty pharmaceutical company earns $-111,630,000.00 in net income (profit) each year or ($3.73) on an earnings per share basis. Paratek Pharmaceuticals employs 50 workers across the globe.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 Park Plz Ste 4, BOSTON, MA 02116-3934, United States. The specialty pharmaceutical company can be reached via phone at +1-617-8076600 or via email at [email protected]


MarketBeat Community Rating for Paratek Pharmaceuticals (PRTK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  259 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  441
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Paratek Pharmaceuticals (NASDAQ:PRTK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.143.143.143.13
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $42.71$42.71$42.71$39.50
Price Target Upside: 128.42% upside128.42% upside91.12% upside62.89% upside

Paratek Pharmaceuticals (NASDAQ:PRTK) Consensus Price Target History

Price Target History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ:PRTK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2018Cantor FitzgeraldSet Price TargetBuy$50.00LowView Rating Details
10/24/2017Robert W. BairdReiterated RatingBuy$40.00N/AView Rating Details
10/24/2017GuggenheimInitiated CoverageBuy$44.00N/AView Rating Details
8/24/2017Raymond James FinancialReiterated RatingStrong-Buy$36.00MediumView Rating Details
7/18/2017HC WainwrightBoost Price TargetPositive -> Buy$36.00 -> $43.00HighView Rating Details
4/4/2017BTIG ResearchBoost Price TargetBuy$47.00 -> $56.00MediumView Rating Details
4/3/2017WedbushReiterated RatingOutperform -> Outperform$30.00HighView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$23.00N/AView Rating Details
6/17/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$46.00 -> $52.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Paratek Pharmaceuticals (NASDAQ:PRTK) Earnings History and Estimates Chart

Earnings by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ PRTK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018($0.75)N/AView Earnings Details
11/8/2017Q3 2017($0.93)($0.77)$0.01 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.89)($0.64)$7.50 million$7.51 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.20)($1.14)$0.02 millionViewListenView Earnings Details
3/2/2017Q4 2016($1.33)($1.17)$0.03 millionViewListenView Earnings Details
11/2/2016($1.38)($1.04)ViewN/AView Earnings Details
8/4/2016Q2 2016($1.66)($1.69)ViewN/AView Earnings Details
5/2/2016($1.25)($1.77)ViewN/AView Earnings Details
2/23/2016Q4($1.18)($1.20)ViewListenView Earnings Details
11/12/2015Q315($0.91)($1.33)ViewListenView Earnings Details
8/5/2015Q215($0.75)($0.94)$3.62 billionViewN/AView Earnings Details
5/15/2015Q1 2015($2.16)($0.96)ViewN/AView Earnings Details
4/2/2015Q1($2.16)($0.74)$0.13 million$4.00 millionViewN/AView Earnings Details
5/5/2014($0.18)($0.15)$0.42 millionViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.29)$0.50 million$0.32 millionViewN/AView Earnings Details
11/7/2013Q3 2013($2.52)($3.00)$0.10 million$0.38 millionViewN/AView Earnings Details
8/7/2013Q2 2013($3.48)($2.40)$0.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.42)($0.56)($5.83) millionViewN/AView Earnings Details
2/27/2013Q4 2012($3.12)($4.20)ViewN/AView Earnings Details
11/12/2012Q312$0.06$0.25$8.37 million$10.44 millionViewN/AView Earnings Details
8/13/2012Q2 2012($3.60)($3.60)ViewN/AView Earnings Details
5/14/2012Q1 2012($5.28)($4.47)ViewN/AView Earnings Details
3/14/2012Q4 2011$4.20$4.42ViewN/AView Earnings Details
11/10/2011Q3 2011($4.92)($4.43)ViewN/AView Earnings Details
8/11/2011Q2 2011($3.36)($2.04)ViewN/AView Earnings Details
5/16/2011Q1 2011($3.24)($1.68)ViewN/AView Earnings Details
3/16/2011Q4 2010($3.36)($2.35)ViewN/AView Earnings Details
11/11/2010Q3 2010($2.64)($2.47)ViewN/AView Earnings Details
8/9/2010Q2 2010($1.80)($1.85)ViewN/AView Earnings Details
5/12/2010Q1 2010($2.04)($1.66)ViewN/AView Earnings Details
3/23/2010Q4 2009($2.76)($2.11)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.12)($3.47)ViewN/AView Earnings Details
8/14/2009Q2 2009($6.53)ViewN/AView Earnings Details
5/13/2009Q1 2009($11.38)ViewN/AView Earnings Details
3/23/2009Q4 2008($15.71)ViewN/AView Earnings Details
11/10/2008Q3 2008($15.97)ViewN/AView Earnings Details
5/12/2008Q1 2008($13.21)($2.76)ViewN/AView Earnings Details
3/17/2008Q4 2007($5.40)($6.24)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Paratek Pharmaceuticals (NASDAQ:PRTK) Earnings Estimates

2018 EPS Consensus Estimate: ($3.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.95)($0.86)($0.91)
Q2 20182($1.02)($0.89)($0.96)
Q3 20182($1.26)($0.48)($0.87)
Q4 20182($1.19)($0.73)($0.96)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Paratek Pharmaceuticals (NASDAQ:PRTK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2014special$1.336/4/20145/26/20146/3/2014
(Data available from 1/1/2013 forward)

Insider Trades

Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 74.55%
Insider Trades by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2018Adam WoodrowVPSell14,333$13.87$198,798.7162,367View SEC Filing  
2/5/2018Douglas W PaganCFOSell16,291$14.22$231,658.0239,570View SEC Filing  
2/5/2018Evan LohCOOSell3,040$14.22$43,228.80144,870View SEC Filing  
2/5/2018Michael BighamChairmanSell4,000$14.22$56,880.00123,680View SEC Filing  
2/5/2018Robert S RadieDirectorSell3,000$14.22$42,660.009,330View SEC Filing  
7/5/2017Adam WoodrowVPSell3,800$23.58$89,604.0069,500View SEC Filing  
7/5/2017Douglas W PaganCFOSell4,139$23.58$97,597.6260,000View SEC Filing  
7/5/2017Evan LohCOOSell4,351$23.58$102,596.58112,783View SEC Filing  
7/5/2017Michael BighamChairmanSell5,075$23.58$119,668.50109,500View SEC Filing  
6/19/2017Douglas W PaganCFOSell4,595$25.00$114,875.0051,000View SEC Filing  
2/6/2017Douglas W PaganCFOSell3,405$15.09$51,381.4558,983View SEC Filing  
2/6/2017Evan LohCOOSell3,106$15.09$46,869.54102,873View SEC Filing  
2/6/2017Michael BighamChairmanSell5,000$15.09$75,450.0099,970View SEC Filing  
6/27/2016Fund Iv L.P. OmegaMajor ShareholderBuy461,538$13.00$5,999,994.00View SEC Filing  
6/23/2016Michael BighamCEOBuy20,000$13.45$269,000.00100,000View SEC Filing  
12/11/2015Evan LohCMOBuy2,300$16.87$38,801.0080,389View SEC Filing  
5/29/2015Hbm Healthcare Investments (CaMajor ShareholderSell20,580$30.75$632,835.00View SEC Filing  
12/13/2013Roumell Asset Management, Llcmajor shareholderSell1,470$3.54$5,203.80View SEC Filing  
12/11/2013Roumell Asset Management, Llcmajor shareholderSell10,490$3.55$37,239.50View SEC Filing  
12/6/2013Roumell Asset Management, Llcmajor shareholderSell8,710$3.54$30,833.40View SEC Filing  
12/4/2013Roumell Asset Management, Llcmajor shareholderSell7,120$3.50$24,920.00View SEC Filing  
11/20/2013Roumell Asset Management, Llcmajor shareholderSell10,040$3.57$35,842.80View SEC Filing  
11/12/2013Roumell Asset Management, Llcmajor shareholderSell7,190$3.53$25,380.70View SEC Filing  
11/7/2013Roumell Asset Management, Llcmajor shareholderSell4,960$3.61$17,905.60View SEC Filing  
10/30/2013Roumell Asset Management, LlcMajor ShareholderSell7,020$3.69$25,903.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Paratek Pharmaceuticals (NASDAQ PRTK) News Headlines

Source:
DateHeadline
Paratek Pharmaceuticals (PRTK) Stock Rating Lowered by Zacks Investment ResearchParatek Pharmaceuticals (PRTK) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 24 at 4:30 PM
Paratek Pharmaceuticals (PRTK) Raised to Buy at Zacks Investment ResearchParatek Pharmaceuticals (PRTK) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - February 22 at 9:56 AM
Paratek Pharmaceuticals (PRTK) to Release Earnings on ThursdayParatek Pharmaceuticals (PRTK) to Release Earnings on Thursday
www.americanbankingnews.com - February 22 at 2:32 AM
Paratek Pharmaceuticals (PRTK) Upgraded to "Buy" at Zacks Investment ResearchParatek Pharmaceuticals (PRTK) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - February 17 at 1:18 PM
Zacks Investment Research Downgrades Paratek Pharmaceuticals (PRTK) to HoldZacks Investment Research Downgrades Paratek Pharmaceuticals (PRTK) to Hold
www.americanbankingnews.com - February 17 at 8:46 AM
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018
finance.yahoo.com - February 15 at 8:35 AM
$5.00 Million in Sales Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter$5.00 Million in Sales Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter
www.americanbankingnews.com - February 10 at 2:46 AM
Paratek Pharmaceuticals (PRTK) Upgraded at Zacks Investment ResearchParatek Pharmaceuticals (PRTK) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 9 at 12:06 PM
Evan Loh Sells 3,040 Shares of Paratek Pharmaceuticals Inc (PRTK) StockEvan Loh Sells 3,040 Shares of Paratek Pharmaceuticals Inc (PRTK) Stock
www.americanbankingnews.com - February 8 at 4:02 AM
Insider Selling: Paratek Pharmaceuticals Inc (PRTK) Director Sells 3,000 Shares of StockInsider Selling: Paratek Pharmaceuticals Inc (PRTK) Director Sells 3,000 Shares of Stock
www.americanbankingnews.com - February 8 at 4:02 AM
Insider Selling: Paratek Pharmaceuticals Inc (PRTK) Chairman Sells 4,000 Shares of StockInsider Selling: Paratek Pharmaceuticals Inc (PRTK) Chairman Sells 4,000 Shares of Stock
www.americanbankingnews.com - February 8 at 4:02 AM
Insider Selling: Paratek Pharmaceuticals Inc (PRTK) VP Sells 14,333 Shares of StockInsider Selling: Paratek Pharmaceuticals Inc (PRTK) VP Sells 14,333 Shares of Stock
www.americanbankingnews.com - February 8 at 12:46 AM
Paratek Pharmaceuticals Inc (PRTK) CFO Douglas W. Pagan Sells 16,291 SharesParatek Pharmaceuticals Inc (PRTK) CFO Douglas W. Pagan Sells 16,291 Shares
www.americanbankingnews.com - February 8 at 12:46 AM
Paratek (PRTK) Completes Submission of NDA for Oral and Intravenous Omadacycline for Pneumonia and Skin InfectionsParatek (PRTK) Completes Submission of NDA for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections
www.streetinsider.com - February 5 at 9:16 AM
Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin InfectionsParatek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections
finance.yahoo.com - February 5 at 9:16 AM
Paratek Pharmaceuticals (PRTK) Rating Lowered to Strong Sell at ValuEngineParatek Pharmaceuticals (PRTK) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - February 4 at 5:02 PM
Paratek Pharmaceuticals Inc (PRTK) Given Consensus Recommendation of "Buy" by AnalystsParatek Pharmaceuticals Inc (PRTK) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 2 at 5:46 AM
Paratek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Healthcare ConferenceParatek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - January 31 at 9:39 AM
Paratek Pharmaceuticals Inc (PRTK) Expected to Announce Quarterly Sales of $5.00 MillionParatek Pharmaceuticals Inc (PRTK) Expected to Announce Quarterly Sales of $5.00 Million
www.americanbankingnews.com - January 24 at 2:10 AM
Paratek Pharmaceuticals (PRTK) Rating Lowered to Hold at Zacks Investment ResearchParatek Pharmaceuticals (PRTK) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 18 at 12:10 PM
Paratek Pharmaceuticals (PRTK) Prices 3.21M Share Common Offering at ~$15.60/Sh - StreetInsider.comParatek Pharmaceuticals (PRTK) Prices 3.21M Share Common Offering at ~$15.60/Sh - StreetInsider.com
www.streetinsider.com - January 18 at 11:16 AM
Pre-Open Movers 01/18: (ESIO) (GNC) (NBEV) Higher; (ARWR) (PRTK) (ALB) Lower (more...) - StreetInsider.comPre-Open Movers 01/18: (ESIO) (GNC) (NBEV) Higher; (ARWR) (PRTK) (ALB) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 18 at 11:16 AM
Paratek Announces Pricing of Public Offering of Common StockParatek Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 18 at 11:16 AM
Paratek Announces Public Offering of Common StockParatek Announces Public Offering of Common Stock
finance.yahoo.com - January 17 at 4:39 PM
Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EUVertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU
finance.yahoo.com - January 11 at 10:43 AM
Paratek Pharmaceuticals Inc (PRTK) Receives Consensus Recommendation of "Buy" from BrokeragesParatek Pharmaceuticals Inc (PRTK) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 8 at 3:54 AM
Zacks: Brokerages Anticipate Paratek Pharmaceuticals Inc (PRTK) Will Announce Quarterly Sales of $5.00 MillionZacks: Brokerages Anticipate Paratek Pharmaceuticals Inc (PRTK) Will Announce Quarterly Sales of $5.00 Million
www.americanbankingnews.com - January 7 at 5:06 AM
-$0.72 Earnings Per Share Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter-$0.72 Earnings Per Share Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter
www.americanbankingnews.com - January 5 at 9:14 PM
Paratek Pharmaceuticals (PRTK) Given a $50.00 Price Target by Cantor Fitzgerald AnalystsParatek Pharmaceuticals (PRTK) Given a $50.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - January 3 at 7:12 PM
Paratek Pharmaceuticals (PRTK) Provides Pipeline Update - StreetInsider.comParatek Pharmaceuticals (PRTK) Provides Pipeline Update - StreetInsider.com
www.streetinsider.com - January 3 at 4:38 PM
Paratek Provides Update on Pipeline ProgressParatek Provides Update on Pipeline Progress
finance.yahoo.com - January 3 at 9:36 AM
Paratek Pharmaceuticals (PRTK) Downgraded by ValuEngine to Strong SellParatek Pharmaceuticals (PRTK) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - December 29 at 5:48 PM
Paratek Pharmaceuticals (PRTK) and Rigel Pharmaceuticals (RIGL) Critical ReviewParatek Pharmaceuticals (PRTK) and Rigel Pharmaceuticals (RIGL) Critical Review
www.americanbankingnews.com - December 22 at 5:54 PM
FDA Accepts New Drug Application For Seysara™ (Sarecycline) For The Treatment Of Moderate To Severe AcneFDA Accepts New Drug Application For Seysara™ (Sarecycline) For The Treatment Of Moderate To Severe Acne
finance.yahoo.com - December 20 at 4:34 PM
 Analysts Anticipate Paratek Pharmaceuticals Inc (PRTK) Will Announce Earnings of -$0.72 Per Share Analysts Anticipate Paratek Pharmaceuticals Inc (PRTK) Will Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - December 20 at 11:26 AM
Biotech Stocks Research Reports Released on Paratek Pharma, MannKind, Array BioPharma, and INSYS TherapeuticsBiotech Stocks' Research Reports Released on Paratek Pharma, MannKind, Array BioPharma, and INSYS Therapeutics
www.bizjournals.com - December 20 at 10:24 AM
$5.00 Million in Sales Expected for Paratek Pharmaceuticals, Inc. (PRTK) This Quarter$5.00 Million in Sales Expected for Paratek Pharmaceuticals, Inc. (PRTK) This Quarter
www.americanbankingnews.com - December 4 at 10:06 AM
Paratek Pharmaceuticals (PRTK) Lowered to "Strong Sell" at BidaskClubParatek Pharmaceuticals (PRTK) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - December 2 at 11:54 AM
Paratek Pharmaceuticals, Inc. (PRTK) Given Average Recommendation of "Buy" by BrokeragesParatek Pharmaceuticals, Inc. (PRTK) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 19 at 3:44 AM
 Analysts Expect Paratek Pharmaceuticals, Inc. (PRTK) to Announce -$0.75 EPS Analysts Expect Paratek Pharmaceuticals, Inc. (PRTK) to Announce -$0.75 EPS
www.americanbankingnews.com - November 14 at 5:14 AM
Brokers Issue Forecasts for Paratek Pharmaceuticals, Inc.s FY2017 Earnings (PRTK)Brokers Issue Forecasts for Paratek Pharmaceuticals, Inc.'s FY2017 Earnings (PRTK)
www.americanbankingnews.com - November 13 at 2:34 AM
FY2017 EPS Estimates for Paratek Pharmaceuticals, Inc. (PRTK) Raised by AnalystFY2017 EPS Estimates for Paratek Pharmaceuticals, Inc. (PRTK) Raised by Analyst
www.americanbankingnews.com - November 13 at 2:34 AM
Paratek Pharmaceuticals, Inc. (PRTK) Expected to Earn FY2021 Earnings of $0.30 Per ShareParatek Pharmaceuticals, Inc. (PRTK) Expected to Earn FY2021 Earnings of $0.30 Per Share
www.americanbankingnews.com - November 10 at 8:11 PM
First Week Of November 17th Options Trading For Paratek Pharmaceuticals (PRTK)First Week Of November 17th Options Trading For Paratek Pharmaceuticals (PRTK)
www.thestreet.com - November 9 at 11:56 AM
Paratek Pharmaceuticals Inc to Host Earnings CallParatek Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - November 9 at 11:56 AM
Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018
finance.yahoo.com - November 9 at 11:56 AM
Paratek reports 3Q lossParatek reports 3Q loss
finance.yahoo.com - November 9 at 11:56 AM
Edited Transcript of PRTK earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of PRTK earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 11:56 AM
CAM Group Holding A Buys Insmed Inc, Zimmer Biomet Holdings Inc, Vertex Pharmaceuticals Inc, ...CAM Group Holding A Buys Insmed Inc, Zimmer Biomet Holdings Inc, Vertex Pharmaceuticals Inc, ...
www.nasdaq.com - November 7 at 9:03 AM
Paratek Pharmaceuticals, Inc. (PRTK) Lifted to Hold at Zacks Investment ResearchParatek Pharmaceuticals, Inc. (PRTK) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - November 1 at 6:34 AM

SEC Filings

Paratek Pharmaceuticals (NASDAQ:PRTK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Paratek Pharmaceuticals (NASDAQ:PRTK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Paratek Pharmaceuticals (NASDAQ PRTK) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.